Pharmafile Logo
Pharmafocus logo
Advanced Search

ticagrelor

Showing 8 posts of 8 posts found.

astrazeneca-sign

AstraZeneca’s Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals

September 7, 2017
Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, pharma, pharmaceutical, ticagrelor, trial

AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …

News
astrazeneca_building_white

Thousands to benefit with new anti-clotting drug recommendation, says NICE

August 12, 2016
Medical Communications, Sales and Marketing AstraZeneca, Brilique, ticagrelor

The National Institute for Health and Care Excellence (NICE) has published new draft guidance recommending AstraZeneca’s Brilique (ticagrelor) for people …

News
astrazeneca image

AstraZeneca looks to oncology match-ups to boost sales

April 24, 2015
Sales and Marketing AstraZeneca, Brilinta, Celgene, Innate, Juno, farxiga, ticagrelor

AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …

News
Brilinta image

Mixed results for AstraZeneca in high-profile Brilinta study

March 17, 2015
Sales and Marketing American College of Cardiology, AstraZeneca, Brilinta, EMA, FDA, ticagrelor

Experts say AstraZeneca is at risk of ‘diminishing returns’ in the clinical advantages of its blood-thinning drug Brilinta, after it …

News
Brilinta image

AstraZeneca’s troubled Brilinta gets welcome lift

January 14, 2015
Sales and Marketing AstraZeneca, Brilinta, FDA, US Department of Justice, acute coronary syndrome, ticagrelor

AstraZeneca has reported positive primary endpoint results for its anti-clogging drug Brilinta to treat patients who have had a heart …

News
brilinta image

EMA questions Brilinta data

November 8, 2013
Sales and Marketing Brilinta, EMA, astrazenca, heart, ticagrelor

The European Medicines Agency is demanding more information from AstraZeneca on its troubled heart pill Brilinta. This rounds off a …

News

Efient fails to prove superiority to Plavix

August 29, 2012
Brillinta, Efient, Plavix, prasugrel, ticagrelor

Daiichi Sankyo and Lilly’s heart drug Efient has failed to come up to the mark in a late-stage trial which …

News

AZ’s Brilique approved in Europe

December 7, 2010
Sales and Marketing AZ, AstraZeneca, Brilique, Plavix, acute coronary syndromes, antiplatelet, atherothrombotic events, ticagrelor

European regulator have approved AstraZeneca’s oral antiplatelet Brilique (ticagrelor tablets). Brilique can now be used for the prevention of atherothrombotic …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024